Literature DB >> 33307021

AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achieve Weight Loss in the Management of Nonalcoholic Fatty Liver Disease: Expert Review.

Zobair M Younossi1, Kathleen E Corey2, Joseph K Lim3.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease, with global public health impact affecting more than 25% of the global population. NAFLD is associated with significant morbidity and mortality from cirrhosis, hepatocellular carcinoma, solid organ malignancies, diabetes mellitus, cardiovascular disease, and obstructive sleep apnea, resulting in significant health care resource use and decreased health-related quality of life. NAFLD cirrhosis is a leading indication for liver transplantation in the United States. Lifestyle modification to achieve weight loss remains a first-line intervention in patients with NAFLD. We summarize evidence-based interventions for lifestyle modification in the treatment of NAFLD and provided best practice advice statements to address key issues in clinical management.
Copyright © 2021 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cirrhosis; Diet; Exercise; Fatty Liver; Liver Fibrosis; NASH; Obesity; Steatohepatitis; Weight Loss

Year:  2020        PMID: 33307021     DOI: 10.1053/j.gastro.2020.11.051

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  40 in total

1.  Hsa_circ_NOTCH3 regulates ZNF146 through sponge adsorption of miR-875-5p to promote tumorigenesis of hepatocellular carcinoma.

Authors:  Lei Bao; Min Wang; Qiqi Fan
Journal:  J Gastrointest Oncol       Date:  2021-10

Review 2.  Clinical practice advice on lifestyle modification in the management of nonalcoholic fatty liver disease in Japan: an expert review.

Authors:  Yoshihiro Kamada; Hirokazu Takahashi; Masahito Shimizu; Takumi Kawaguchi; Yoshio Sumida; Hideki Fujii; Yuya Seko; Shinya Fukunishi; Katsutoshi Tokushige; Atsushi Nakajima; Takeshi Okanoue
Journal:  J Gastroenterol       Date:  2021-10-31       Impact factor: 7.527

Review 3.  Menopausal hormone therapy in women with dyslipidemia and nonalcoholic fatty liver disease.

Authors:  Stergios A Polyzos; Irene Lambrinoudaki; Dimitrios G Goulis
Journal:  Hormones (Athens)       Date:  2022-05-09       Impact factor: 3.419

4.  Editorial: The Role of Nutrition in the Management of Liver and Associated Diseases.

Authors:  Naga Betrapally
Journal:  Front Nutr       Date:  2022-06-10

Review 5.  Growth Hormone and Insulin-Like Growth Factor 1 Regulation of Nonalcoholic Fatty Liver Disease.

Authors:  Laura E Dichtel; Jose Cordoba-Chacon; Rhonda D Kineman
Journal:  J Clin Endocrinol Metab       Date:  2022-06-16       Impact factor: 6.134

6.  NASH/Liver Fibrosis Prevalence and Incidence of Nonliver Comorbidities among People with NAFLD and Incidence of NAFLD by Metabolic Comorbidities: Lessons from South Korea.

Authors:  Jiyoon Park; Eunice Yewon Lee; Jie Li; Mi Jung Jun; Eileen Yoon; Sang Bong Ahn; Chuanli Liu; Hongli Yang; Fajuan Rui; Biyao Zou; Linda Henry; Dong Hyun Lee; Dae Won Jun; Ramsey C Cheung; Mindie H Nguyen
Journal:  Dig Dis       Date:  2021-02-03       Impact factor: 2.404

7.  Multivariable-adjusted trends in mortality due to alcoholic liver disease among adults in the United States, from 1999-2017.

Authors:  Emily Ryu; Harry H Xia; Grace L Guo; Lanjing Zhang
Journal:  Am J Transl Res       Date:  2022-02-15       Impact factor: 4.060

8.  Combined analysis of gut microbiota, diet and PNPLA3 polymorphism in biopsy-proven non-alcoholic fatty liver disease.

Authors:  Sonja Lang; Anna Martin; Xinlian Zhang; Fedja Farowski; Hilmar Wisplinghoff; Maria J G T Vehreschild; Marcin Krawczyk; Angela Nowag; Anne Kretzschmar; Claus Scholz; Philipp Kasper; Christoph Roderburg; Raphael Mohr; Frank Lammert; Frank Tacke; Bernd Schnabl; Tobias Goeser; Hans-Michael Steffen; Münevver Demir
Journal:  Liver Int       Date:  2021-05-07       Impact factor: 8.754

Review 9.  Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease.

Authors:  Fasiha Kanwal; Jay H Shubrook; Leon A Adams; Kim Pfotenhauer; Vincent Wai-Sun Wong; Eugene Wright; Manal F Abdelmalek; Stephen A Harrison; Rohit Loomba; Christos S Mantzoros; Elisabetta Bugianesi; Robert H Eckel; Lee M Kaplan; Hashem B El-Serag; Kenneth Cusi
Journal:  Gastroenterology       Date:  2021-09-20       Impact factor: 33.883

10.  Influence of Psychological Biomarkers on Therapeutic Adherence by Patients with Non-Alcoholic Fatty Liver Disease: A Moderated Mediation Model.

Authors:  Jesús Funuyet-Salas; Agustín Martín-Rodríguez; María Ángeles Pérez-San-Gregorio; Manuel Romero-Gómez
Journal:  J Clin Med       Date:  2021-05-20       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.